RT Journal Article
SR Electronic
T1 Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.03.22270393
DO 10.1101/2022.02.03.22270393
A1 Österdahl, Marc F.
A1 Christakou, Eleni
A1 Hart, Deborah
A1 Harris, Ffion
A1 Shahrabi, Yasaman
A1 Pollock, Emily
A1 Wadud, Muntaha
A1 Spector, Tim D.
A1 Brown, Matthew A.
A1 Seow, Jeffrey
A1 Malim, Michael H.
A1 Steves, Claire J.
A1 Doores, Katie J.
A1 Duncan, Emma L
A1 Tree, Timothy
YR 2022
UL http://medrxiv.org/content/early/2022/02/03/2022.02.03.22270393.abstract
AB Objectives To assess T cell responses in individuals with and without a positive antibody response to SARS-CoV-2, in symptomatic and asymptomatic individuals during the COVID-19 pandemic.Methods Participants were drawn from the TwinsUK cohort, selected according to a) presence or absence of COVID-associated symptoms (S+, S-), logged prospectively through the COVID Symptom Study app, and b) Anti-IgG Spike and anti-IgG Nucleocapsid antibodies measured by ELISA (Ab+, Ab-), during the first wave of the UK pandemic. T cell helper and regulatory responses after stimulation with SARS-CoV-2 peptides were assessed.Results 32 participants were included in final analysis. 14 of 15 with IgG Spike antibodies had a T cell response to SARS-CoV-2-specific peptides; none of 17 participants without IgG Spike antibodies had a T cell response (Chi-squared 28.2, p<0.001). Quantitative T cell responses correlated strongly with fold-change in IgG Spike antibody titre (rho=0.79, p<0.0001) but not to symptom score (rho=0.17, p=0.35).Conclusions Humoral and cellular immune responses to SARS-CoV-2 are highly correlated, with no evidence that cellular immunity differs from antibody status four months after acute illness.Competing Interest StatementTDS has received payment for scientific consultancy services to ZOE Global Ltd. No other authors have competing interests to declareFunding StatementThe study was funded by the Huo Family Foundation Award to MHM and KJD, the UKRI and MRC Genotype-to-Phenotype UK National Virology Consortium (MR/W005611/1 to MHM and KJD), the Chronic Disease Research Foundation (CDRF-22/2020 to TS, MAB, CJS, MHM, KJD and ELD), Wellcome Trust Investigator Award 106223/Z/14/Z to MHM, and the Department of Health via a National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, European Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd and the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College LondonAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The TwinsUK study was approved by NHS London - London-Westminster Research Ethics Committee (REC reference EC04/015), and Guy's and St Thomas' NHS Foundation Trust Research and Development (R&D). The TwinsUK Biobank was approved by NHS North West - Liverpool East Research Ethics Committee (Reference: 19/NW/0187), IRAS ID 258513. All participants provide written, informed consent. The CSS was approved by KCL Ethics Committee (REMAS ID 18210, review reference LRS-19/20-18210). Upon registration, all subscribers provide consent for their data to be available for COVID-19 research. Participant samples for the ROC analysis were originally approved for use by the London- Bromley Research Ethics Committee (Reference: 08/H0805/14), with extension permitted under the extended Control of Patient Information (COPI) notice 2020/21 and specific approval from the Committee Chair for this study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected in the COVID Symptom Study smartphone application are shared with other health researchers through the UK National Health Service-funded Health Data Research UK (HDRUK) and Secure Anonymised Information Linkage consortium, housed in the UK Secure Research Platform (Swansea, UK). Anonymised data are available to be shared with researchers according to their protocols in the public interest (https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259). The TwinsUK Resource Executive Committee (TREC) oversees management, data sharing and collaborations involving the TwinsUK registry (for further details see https://twinsuk.ac.uk/resources-for-researchers/access-our-data/). Data relevant to T-Cell and B-Cell testing may be discussed with the authors. COVID-19Coronavirus Disease 2019CSSCOVID Symptom StudyDMSODimethyl SulfoxideELISAenzyme-linked immunosorbent assaysSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2PBMCsperipheral blood mononuclear cellsREMASResearch Ethics Management Application SystemROCreceiver operator characteristic